August 29, 2022
Ian D. Davis, MBBS, PhD, spoke about the TheraP study which evaluated 177Lu-PSMA-617 vs cabazitaxel in patients with metastatic castration-resistant prostate cancer.
August 13, 2022
Ian D. Davis, MBBS, PhD, spoke about the subgroup analysis of the ENZAMET trial which analyzed enzalutamide in metastatic hormone-sensitive prostate cancer.
August 01, 2022
Ian D. Davis, MBBS, PhD, spoke about updated survival results of the ENZAMET trial which analyzed enzalutamide in metastatic hormone-sensitive prostate cancer.